12/22
11:20 am
dwtx
Dogwood Therapeutics Says Interim Phase 2B Data Show Pain Improvement With Halneuron [Yahoo! Finance]
Low
Report
Dogwood Therapeutics Says Interim Phase 2B Data Show Pain Improvement With Halneuron [Yahoo! Finance]
12/22
11:00 am
dwtx
Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain [Yahoo! Finance]
High
Report
Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain [Yahoo! Finance]
12/22
10:15 am
dwtx
Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain
High
Report
Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain
12/13
01:10 am
dwtx
Dogwood Therapeutics (NASDAQ:DWTX) was downgraded by analysts at
Wall St
Medium
Report
Dogwood Therapeutics (NASDAQ:DWTX) was downgraded by analysts at
Wall St
11/26
01:14 pm
dwtx
Chemotherapy-induced Peripheral Neuropathy Treatment Market Poised for Strong Growth Throughout the Forecast Period (2025–2034) Amid Rising Chemotherapy Adoption | DelveInsight [Yahoo! Finance]
Low
Report
Chemotherapy-induced Peripheral Neuropathy Treatment Market Poised for Strong Growth Throughout the Forecast Period (2025–2034) Amid Rising Chemotherapy Adoption | DelveInsight [Yahoo! Finance]
11/6
08:45 am
dwtx
Dogwood Therapeutics Reports Third Quarter 2025 Financial Results
Medium
Report
Dogwood Therapeutics Reports Third Quarter 2025 Financial Results
10/8
12:19 pm
dwtx
Dogwood Therapeutics (NASDAQ:DWTX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Dogwood Therapeutics (NASDAQ:DWTX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
10/7
09:10 am
dwtx
Dogwood Therapeutics, Inc. Chief Medical Officer, Dr. Michael Gendreau, to Present an Overview of the Halneuron® Pain Research Program at the 19th Annual Pain Therapeutics Summit [Yahoo! Finance]
Medium
Report
Dogwood Therapeutics, Inc. Chief Medical Officer, Dr. Michael Gendreau, to Present an Overview of the Halneuron® Pain Research Program at the 19th Annual Pain Therapeutics Summit [Yahoo! Finance]
9/30
08:06 am
dwtx
Dogwood Therapeutics (NASDAQ:DWTX) had its price target raised by analysts at HC Wainwright from $10.00 to $12.00. They now have a "buy" rating on the stock.
Medium
Report
Dogwood Therapeutics (NASDAQ:DWTX) had its price target raised by analysts at HC Wainwright from $10.00 to $12.00. They now have a "buy" rating on the stock.
9/29
08:03 am
dwtx
Dogwood Therapeutics Secures Exclusive Worldwide, Royalty Free License to Develop and Commercialize SP16 as a Treatment for Cancer Related Pain in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer Patients [Y
High
Report
Dogwood Therapeutics Secures Exclusive Worldwide, Royalty Free License to Develop and Commercialize SP16 as a Treatment for Cancer Related Pain in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer Patients [Y
9/29
07:15 am
dwtx
Dogwood Therapeutics Secures Exclusive Worldwide, Royalty Free License to Develop and Commercialize SP16 as a Treatment for Cancer Related Pain in an All-Stock Transaction Underscoring the Company’s Dedication to Improving the Lives of Cancer Patients
High
Report
Dogwood Therapeutics Secures Exclusive Worldwide, Royalty Free License to Develop and Commercialize SP16 as a Treatment for Cancer Related Pain in an All-Stock Transaction Underscoring the Company’s Dedication to Improving the Lives of Cancer Patients